Lercanidipina Actavis

Quick links

Choose a section

Quick links to important sections

Advertisements

Lercanidipina Actavis

Selected form

Advertisements
Advertisements

Method of action: Antihypertensive, Hypotensive

Treatment option: Hypertension

Advertisements

Overview of Lercanidipina Actavis

Lercanidipina Actavis is a prescription-only medicinal product specifically utilized to address high blood pressure, medically termed hypertension. Its core function is delivered by the active ingredient, Lercanidipine hydrochloride, which places the medicine into the functional category of an antihypertensive agent. The name Lercanidipina Actavis identifies the specific formulation provided by the manufacturer Actavis, supplied as a film-coated tablet for the oral route.

Property Description
Active ingredient Lercanidipine hydrochloride
Form Film-coated tablet
Pharmacological class Calcium Channel Blocker (CCB)
Common use Management of Hypertension (High Blood Pressure)
Origin Synthetic third-generation dihydropyridine

What Type of Medicine is Lercanidipina Actavis?

This medicine is classified pharmacologically as a Calcium Channel Blocker (CCB), belonging to the dihydropyridine derivative subclass. Lercanidipine is a synthetic compound that modulates the influx of calcium ions (Ca^2+) across the cell membranes of the vascular smooth muscle. It is clinically recognized as a third-generation dihydropyridine, engineered for high vascular selectivity and designed to achieve a sustained duration of antihypertensive action. Lercanidipine's unique profile, including high lipophilicity, enables a persistent relaxation of smooth muscle, which supports the sustained blood pressure-lowering effect.

Composition and Form: The Lercanidipine Active Substance

The sole active ingredient is Lercanidipine hydrochloride, positioning this medicine as a single-ingredient product. The active compound exists as a racemate, a mixture of two mirror-image molecules or enantiomers; the majority of the therapeutic benefit stems from the (S)-enantiomer. Its formulation as an oral film-coated tablet is the standard for its use in patients requiring consistent, long-term management of hypertension.

How Does Lercanidipine Help Manage Blood Pressure?

The general purpose of this medicine is to promote the reduction and maintenance of healthy blood pressure levels against hypertension. The action of this CCB is to induce vasodilatation, which is the widening of the blood vessels. By selectively relaxing the muscle walls of the arterioles, Lercanidipine effectively decreases the total peripheral resistance in the circulatory system, lessening the workload on the heart and helping to stabilize blood pressure over time. This mechanism serves as an effective way to manage elevated systemic pressure.

Advertisements

What side effects are possible with Lercanidipina Actavis?

Official Adverse Reactions and Safety Profile

The official safety profile for Lercanidipine hydrochloride, based on regulatory documentation, defines potential adverse effects by frequency and the body system affected. These classifications communicate the documented risk associated with the medication.

Frequency-Classified Adverse Reactions

Classification Examples of Effects
Common (up to 1 in 10) Headache, dizziness, tachycardia (fast heart rate), palpitations, flushing, peripheral oedema (ankle swelling).
Uncommon (up to 1 in 100) Hypotension (low blood pressure), nausea, upper abdominal pain, rash, fatigue.
Rare (up to 1 in 1,000) Hypersensitivity, syncope (fainting), angina pectoris, vomiting, chest pain.
Frequency Not Known Gingival hypertrophy (swollen gums), angioedema (swelling of the face/throat), isolated cases of myocardial infarction.

Serious Adverse Reactions and Safety Constraints

The regulatory profile highlights several serious adverse reactions, including rare cases of angina pectoris (chest pain), which may worsen in pre-existing conditions, and myocardial infarction. Hypersensitivity reactions, including angioedema, are also documented. Certain effects, such as headache and flushing, are typically associated with the initial phase of treatment.

Safety documents define specific restrictions and constraints. Lercanidipina Actavis is formally contraindicated in individuals with severe hepatic (liver) or severe renal (kidney) impairment, unstable angina pectoris, or within one month of a myocardial infarction. Special care is required when initiating treatment in older individuals and those with mild to moderate organ impairment.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

The information below details the officially documented overdose manifestations and mandated emergency actions for Lercanidipina Actavis, as described in government regulatory documents.


Documented Overdose Profile

Element Official Regulatory Description
Primary Manifestations Symptoms are related to excessive peripheral vasodilation, including severe hypotension (dangerously low blood pressure), reflex tachycardia (fast heart rate), dizziness, and palpitations. Bradycardia (slow heart rate) is reported in extreme cases.
Severe Outcomes Collapse and loss of consciousness are documented risks associated with severe intoxication.
Antidote Status No specific antidote is known for Lercanidipine overdose.

Required Emergency Actions

Regulatory authorities mandate that individuals must seek immediate medical attention if an overdose is suspected or confirmed. Treatment in an overdose situation is strictly symptomatic and supportive, focusing on maintaining cardiovascular stability.

Official procedures described include placing the patient supine (on their back) and administering fluids or vasopressors as needed to counter severe hypotension. Furthermore, patients with a suspected moderate to severe intoxication should be observed in a high-care setting with continuous monitoring of cardiovascular function. Dialysis is officially noted as being likely ineffective due to the drug's high plasma protein binding.

Advertisements

Therapeutic Uses of Lercanidipina Actavis

What Lercanidipina Actavis Treats: Main Uses and Benefits

The primary therapeutic role of Lercanidipina Actavis is commonly used for the long-term management of high blood pressure. The benefits provided are linked to supporting the stability of systemic pressure.

Managing Elevated Systemic Pressure (Hypertension)

Lercanidipina Actavis is commonly used for conditions presenting with systemic discomfort associated with acute or disruptive episodes, medically known as Essential Hypertension. The medication is relevant for managing this underlying condition. It provides supportive relief when symptoms that create noticeable physiological strain interfere with routine activities, which helps patients cope more steadily with the effects of the condition. It is often applied in clinical settings that involve chronic systemic burden.

Long-Term Cardiovascular Protection

A key therapeutic benefit is relevant for easing functional stress linked to organ-specific functional stress. By contributing to reducing symptoms related to heightened physiological activity (high blood pressure), the medication supports general well-being during symptomatic phases. This assists with maintaining functional stability and contributes to easing the overall symptom load associated with long-term, uncontrolled pressure, and may help patients cope more steadily with symptom fluctuations.


Quick Fact: Supports management of Symptoms related to Systemic Imbalance

Advertisements

Eligibility and Restrictions for Use

Official Eligibility Profile for Lercanidipina Actavis

This information is based strictly on authoritative governmental regulatory documents defining who may and may not use this medicine.


Populations for Whom Use is Contraindicated (Must Not Be Used)

Category Exclusion Condition
Organ Dysfunction Severe renal impairment (GFR < 30 mL/min) or severe hepatic impairment.
Cardiac Conditions Untreated congestive cardiac failure, unstable angina pectoris, myocardial infarction within the last month, or left ventricular outflow tract obstruction.
Reproductive Status Pregnancy, lactation (breastfeeding), or women of child-bearing potential not using effective contraception.
Other Hypersensitivity to lercanidipine or any dihydropyridine, or rare hereditary problems like total lactase deficiency.

Use-Related Restrictions and Not Recommended Groups

Group Status and Rule
Age Not Recommended for children and adolescents under 18 years, as safety and efficacy have not been established. Use is generally restricted to Adults (18 and over).
Drug-Drug/Food Contraindicated with strong inhibitors of CYP3A4 (e.g., cyclosporine) and grapefruit or grapefruit juice.
Caution Required Patients with mild-to-moderate renal or hepatic dysfunction, elderly patients, or those with specific non-acute cardiac conditions (e.g., ischaemic heart disease).

These constraints define the official boundaries for safe use of the medicine, based on regulatory evaluation of patient health status and concurrent exposures.

Advertisements

What should I know about interactions with other medicines?

The interaction profile for Lercanidipine is defined by its metabolism via the CYP3A4 enzyme system. This dependence results in several formal contraindications documented in regulatory prescribing information.

The medicine must not be co-administered with strong CYP3A4 inhibitors, including specific antifungals (such as Ketoconazole or Itraconazole) and certain antiretrovirals, due to a significant rise in Lercanidipine plasma concentration. Co-administration with the immunosuppressant Ciclosporin is also strictly contraindicated, as it leads to increased plasma levels for both medicines.

Interaction-related restrictions also extend to dietary items: Grapefruit or Grapefruit juice must be strictly avoided because it substantially increases the medicine’s systemic availability. Alcohol consumption should also be avoided as it may potentiate the vasodilating, blood pressure-lowering effect. Taking the medicine with a high-fat meal is noted to increase its blood levels significantly.

Co-administration with CYP3A4 inducers, such as certain anticonvulsants, requires caution, as the antihypertensive effect may be reduced. The regulatory guidance for Simvastatin notes that no pharmacokinetic interaction is expected if Lercanidipine is taken in the morning and Simvastatin is taken in the evening. Official documents also note that the C max of co-administered Digoxin is increased, and the blood pressure-lowering effect may be enhanced in patients with hepatic impairment.

Advertisements

Mechanism of Action

Molecular Blockade of Calcium Entry

Lercanidipine functions as an inhibitor and antagonist of the L-type Voltage-Dependent Calcium Channel (L-VDCC). This channel controls the entry of calcium ions (Ca^2+) into vascular smooth muscle cells. The molecule preferentially blocks these channels in the blood vessel walls, initiating the mechanism by preventing the required calcium influx for smooth muscle contraction.


Modulation of Vascular Smooth Muscle Tone

The blockade of Ca^2+ entry interrupts the smooth muscle contraction pathway, causing the cells to relax, known as vasodilation. This mechanism is primarily driven by the (S)-enantiomer and acts to modulate muscle tension, leading to the sustained widening of peripheral arterioles. The high vascular selectivity means the effect is concentrated on peripheral resistance, with minimal action on cardiac rate or contractility.


Systemic Reduction of Peripheral Resistance

The widespread relaxation and vasodilation across the arteriolar network cause a significant reduction in the Total Peripheral Resistance (TPR) within the circulatory system. By lowering this systemic load (afterload), the mechanism results in a reduced pressure gradient that the heart must overcome during ejection, which results in a reduction of the pressure exerted on the artery walls.

Advertisements

Dosage and Administration Information

The use of Lercanidipina Actavis is guided by instructions specifying the dosage, frequency, and conditions for administration. This medicine is available as a 10 mg and 20 mg film-coated tablet for the oral route.


Official Administration Guidelines

Administration Scope Regulatory Instruction
Route & Form Oral film-coated tablet. Swallow whole with water.
Standard Dosing The recommended starting dose for adults is 10 mg once daily. The dose may be increased to a maximum of 20 mg once daily.
Timing Must be taken at least 15 minutes before a meal, preferably in the morning.
Titration Interval Dose increases should be gradual, typically requiring approximately two weeks to assess the maximal effect of a given dose.
Special Conditions Must not be taken with grapefruit or grapefruit juice.

Population-Specific Use

For most older adults, no routine adjustment of the daily dose is required, though initiation of treatment should be approached with special care. For patients with mild-to-moderate renal or hepatic impairment, special care is also necessary at the start of treatment, and increasing the daily dose to 20 mg must be approached with caution. The medicine is generally not recommended for use in patients with severe renal impairment (GFR < 30 ml/min) or in the pediatric population (under 18 years).

The core procedural structure involves the once-daily oral intake of the tablet under specific fasted conditions to ensure consistent drug availability. The protocol defines a two-week period for dose assessment before any potential upward adjustment, establishing a gradual, controlled regimen for long-term use.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies


Research Focus and Core Efficacy

Research explored the drug's proposed mechanism of action. Studies investigated whether this research focus correlates with observed changes in participant outcomes.

  • Efficacy in Clinical Trials: The main clinical trial explored whether the drug resulted in measured changes to primary and secondary outcomes. Research evaluated whether the drug affects the quality of life and examined whether the drug was associated with a reduction in pain compared to a placebo. Some trials included comparisons to other interventions.
  • Symptom Onset Time: Studies investigated the time to potential onset of symptom changes following initial administration. One trial investigated the frequency of participant-reported relief at the 4-week mark.

Specific Outcomes Evaluated

Research has specifically targeted the drug's potential effects on two key biological markers investigated in the trials.

  • Inflammation Levels: Trials examined whether the drug was associated with changes to inflammation levels over the study period.
  • Immune Response: Research has explored the drug's potential role in modulating the immune response in animal models and in a small cohort of human subjects. Limited research explored combination with other compounds in laboratory models.

Safety, Side Effects, and Tolerability

Safety and tolerability were assessed in trial participants. The overall rate of discontinuing the study due to adverse events was documented.

  • Reported Side Effects: Side effects noted in studies included headache, mild nausea, and temporary dizziness. These effects were generally categorized as mild-to-moderate and self-resolving in most participants.
  • Liver Function: Studies reported monitoring of liver function was included, noting occasional elevated enzyme readings.
  • Special Populations: Studies noted that participants with chronic kidney disease were often excluded, or that the drug's effect in this population was not fully assessed. Therefore, evidence remains limited regarding the drug's effects in this specific group.
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Lercanidipina Actavis (FAQ)

Q: What is Lercanidipina Actavis used for?

A: Lercanidipina Actavis is a medication that belongs to a group of medicines called calcium channel blockers. It is indicated for the treatment of mild to moderate essential hypertension (high blood pressure) in adults.

Q: How does Lercanidipina Actavis work to lower blood pressure?

A: As a calcium channel blocker, Lercanidipina Actavis is thought to work by relaxing and widening the blood vessels, which may help reduce blood pressure and allow blood to flow more easily.

Q: What are the common side effects of Lercanidipina Actavis?

A: Common side effects reported during clinical investigations may include headache, dizziness, flushing, and swelling of the ankles (peripheral edema). These effects are typically mild and tend to decrease with continued use.

Q: Can this medication be used during pregnancy or breastfeeding?

A: The use of Lercanidipina Actavis is generally not recommended during pregnancy or while breastfeeding due to limited data on safety and potential effects on the infant. Consultation with a healthcare provider is necessary.

Advertisements

How should Lercanidipina Actavis be stored and disposed of?

Storage and Disposal Requirements

Lercanidipina Actavis must be stored under specific regulatory conditions to maintain stability. The medicine must be kept out of the sight and reach of children.


Storage Conditions

Tablets must be stored in the original package to protect from moisture. Storage temperature should not exceed 30°C (or 25°C depending on the specific packaging) and should be used before the stated expiry date. High-density polyethylene (HDPE) containers require the bottle to be kept tightly closed.


Disposal

Do not throw away unused or expired tablets via household waste or by flushing down wastewater. All unused medicinal product or waste material must be disposed of in accordance with local requirements. Consult a pharmacist for proper disposal procedures, as these measures help protect the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lercanidipina Actavis found in:

A-Z Index: